Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pcDNA3-FLAG-MTOR-C1483F Citations (2)

Originally described in: A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.
Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH, Sabatini DM Cancer Discov. 2014 May;4(5):554-63. doi: 10.1158/2159-8290.CD-13-0929. Epub 2014 Mar 14.
PubMed Journal

Articles Citing pcDNA3-FLAG-MTOR-C1483F

Articles
Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR(T790M)-Mutant NSCLC. Park HR, Kim TM, Lee Y, Kim S, Park S, Ju YS, Kim M, Keam B, Jeon YK, Kim DW, Heo DS. J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02254-1. doi: 10.1016/j.jtho.2021.06.013. PubMed
mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion. Liu HJ, Du H, Khabibullin D, Zarei M, Wei K, Freeman GJ, Kwiatkowski DJ, Henske EP. Nat Commun. 2023 Mar 3;14(1):1214. doi: 10.1038/s41467-023-36881-7. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.